A Phase 1 Study of Givosiran (ALN-AS1) in Patients With Acute Intermittent Porphyria (AIP)
Status:
Completed
Trial end date:
2017-09-06
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and tolerability of givosiran (ALN-AS1)
in AIP patients as well as to characterize pharmacokinetics (PK) and pharmacodynamics (PD) of
ALN-AS1 in AIP patients.